Merck Forms Joint Venture with Sun Pharmaceutical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Forms Joint Venture with Sun Pharmaceutical


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck & Co. formed a joint venture with the Mumbai-based specialty pharmaceutical company Sun Pharmaceutical Industries to develop, manufacture, and commercialize new combinations and formulations of branded generic drugs in emerging markets. The joint venture will be structured through subsidiaries of Merck and Sun Pharmaceutical. A joint board and leadership team, consisting of members of senior management from both companies, will manage the collaboration.


"Merck’s emerging-markets strategy is driven by our overarching focus on applying innovation across our business from introducing novel compounds to broadening our focus on innovative branded generics," said Kevin Ali, president of Merck’s emerging-markets businesses, in an Apr. 11, 2011, press release.

Sun Pharmaceutical manufactures and markets pharmaceutical formulations as branded generic drugs and “incrementally innovative generics” in India, the US, and several emerging markets, said Merck in the release. The company has capabilities in process chemistry, active pharmaceutical ingredient manufacturing, and dosage formulations. Sun also has an independent research and development company, Sun Pharma Advanced Research, which focuses on the discovery and development of new molecules and drug-delivery systems. Its projects include oral drug-delivery platforms (e.g., gastroretentive devices and wrap-matrix technology), injectables (nanoparticulate formulations and biodegradable depots), dry-powder inhalers, and ophthalmic technologies (e.g., swollen micelles and gel-free reservoirs). Some products based on these technologies are marketed in India.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here